Outer Biosciences now feeds live human skin—harvested from discarded surgical tissue and kept viable for more than a month—into machine-learning models. The startup hopes to make drug-discovery and dermatology predictions far more reliable. Its two-year pipeline moves tissue from operating rooms to a lab within hours, a speed the company says preserves the cells’ natural behavior.
Why the old data-sets fall short
For most of biotech’s recent history, researchers have relied on animal models or cultured cell lines to train computational tools. Those systems are cheap and easy to handle, but they rarely capture the full complexity of human skin—a layered organ with immune cells, nerve endings, microbiome interactions and a dynamic response to hormones and stress. The mismatch forces drug developers to run multiple rounds of animal testing and human trials, inflating costs and extending timelines.
Outer Biosciences positions itself as a bridge across that gap. By using tissue that has never been altered in a dish, the company believes its AI can learn patterns invisible to synthetic models. “Living data” is the phrase the team uses to describe the difference between a static snapshot of a cell line and a continuously interacting tissue slice that still communicates with its environment.
From the operating room to the algorithm
The logistical challenge matches the scientific one. Outer Biosciences sources skin that would otherwise be discarded during procedures such as abdominoplasties or mastectomies. Nonprofit and commercial biobanks, operating under Institutional Review Board (IRB) oversight, document donor consent for research use. Once a hospital flags a suitable specimen, the company’s courier network picks it up, transports it in temperature-controlled containers, and delivers it to a processing facility within a few hours.
In the lab, the skin sits in a perfusion system that mimics blood flow, keeping the cells alive for up to 30 days. During that window, the team captures high-resolution imaging, transcriptomics and proteomics data at multiple time points. The multi-modal dataset feeds deep-learning pipelines that predict how the tissue will react to chemical compounds, UV exposure, or inflammatory triggers.
The people pulling the lever
Co-founder and CEO Michael Polansky brings a mathematics background from Harvard and a track record of scaling complex operations, from venture-capital portfolios to global concert tours. Chief Scientist Kyung-Jin Jang, a skin-biology specialist, directs the experimental side, while CTO Chris Hinojosa builds the data-engineering platform that stitches together imaging and molecular streams. The board includes pop-culture icon Lady Gaga, who also chairs the cosmetics brand Haus Labs, a venture that shares research resources with Outer Biosciences.
These cross-industry ties give the startup both the capital to build a niche logistics network and a ready market for early applications. Haus Labs, for example, could test new formulations on the live-tissue platform before moving to human volunteers, potentially shaving weeks off the typical product-development cycle.
What’s at stake
If the approach lives up to its promise, pharmaceutical companies could cut the number of animal studies required for early-stage screening, reducing both cost and ethical concerns. Dermatology clinics might gain AI tools that predict how a patient’s skin will respond to a prescription cream, enabling truly personalized treatment plans. The broader AI community could also benefit from a richer, more realistic training set that pushes the limits of predictive biology.
The model raises questions about scalability and privacy. Collecting tissue from surgery depends on hospitals and donors willing to participate, and the supply chain may bottleneck as demand rises. While biobanks operate under IRB oversight, detailed molecular profiles could, in theory, be linked back to individuals if data-handling practices slip. Critics argue that even with consent, the commercial exploitation of discarded tissue skirts a thin ethical line.
Counter-point: Do organoids still have a role?
Scientists who develop organoids—three-dimensional clusters of cells grown in the lab to mimic organ function—caution against discarding those models entirely. Organoids can be generated from a single patient’s induced pluripotent stem cells, offering a personalized platform without the need for fresh surgical tissue. They also let researchers study developmental processes over months, something a 30-day skin slice cannot do. Outer Biosciences acknowledges that its platform is not a universal replacement but a complementary source of high-fidelity data for specific questions where the native architecture of skin matters most.
The road ahead
Outer Biosciences is currently running pilot studies with several biotech partners, testing the predictive power of its models against known drug outcomes. Early results, shared only in internal briefings, suggest a higher correlation with clinical-trial data than comparable organoid-based predictions. The company plans to expand its tissue collection to include other organ types, though each will bring its own logistical hurdles.
Regulators have not yet issued specific guidance on AI models trained on live human tissue, but the FDA’s emerging framework for AI-driven medical devices will likely intersect with Outer’s work. The startup says it is preparing documentation that meets both data-privacy standards and the agency’s expectations for algorithmic transparency.
Bottom line
Outer Biosciences has turned a logistical feat—moving fresh human skin from the operating room to a lab in a matter of hours—into a data engine that could make AI predictions about drugs and skin health more trustworthy. The venture’s success will hinge on its ability to keep the tissue pipeline flowing, protect donor privacy, and prove that “living data” actually outperforms existing synthetic models. If it does, the ripple effect could be felt across pharma, cosmetics and clinical dermatology, reshaping how we train machines to understand the human body.